PHEX, DMP1, matrix extracellular phosphoglycoprotein (MEPE), and ASARM peptides are proposed to dynamically regulate FGF23 expression in bone
PHEX, DMP1, matrix extracellular phosphoglycoprotein (MEPE), and ASARM peptides are proposed to dynamically regulate FGF23 expression in bone. An indirect pathway (A) predominates in normal physiology and a component direct pathophysiological pathway (B) predominates in familial and tumor forms of rickets/osteomalacia with hypophosphatemia [HYP, autosomal recessive hypophosphatemic rickets (ARHR), ADHR, and tumor-induced osteomalacia for example]. A: indirect ASARM pathway: 1) PHEX (a Zn metalloendopeptidase) is proposed to interact with DMP1 by binding to the DMP1-ASARM motif located at the COOH-terminal region of DMP1 (see also ). The PHEX-DMP1 binding initiates a signaling pathway that reduces FGF23 expression. Note that in support of this, in XLH and ARHR, mutations in “PHEX or DMP1” result in hypophosphatemia through increased FGF23 expression and stability (overlapping pathophysiologies) (, , ). Also, PHEX binds with high affinity and specificity to ASARM peptides or ASARM protein motifs (MEPE, DMP1, and osteopontin derived) and MEPE protein (, , , ). PHEX cleaves ASARM peptides, the only known physiological substrate for PHEX (, , , , ). Also, SIBLINGs (like DMP1) activate PHEX-related Zn matrix metalloproteinases via their binding interactions (, ). DMP1 for example binds and activates a PHEX-related Zn matrix metalloproteinase 9 (MMP9) (). Finally, the in vitro addition of recombinant DMP1 to UMR-106 cells causes a dose-dependent decrease in FGF23 expression (mRNA and protein) (). ASARM peptides are proposed to competitively displace the DMP1-PHEX complex in “normal mice” by forming a high-affinity/specificity PHEX-ASARM complex (, ) that is slowly hydrolyzed (low Kcat/Km) by PHEX (, , ). 2) This causes an upregulation of FGF23. 3) Increased FGF23 expression leads to reduced 1,25 vitamin D3, reduced NPT2a expression, and hypophosphatemia. The competitive displacement of DMP1 by ASARM peptides provides an additional “bone” fine tuning of FGF23 and renal phosphate mineral homeostasis. B: direct pathophysiological ASARM pathway that is independent of FGF23, PHEX, and DMP1 is proposed to occur in familial HYP, ARHR, and ADHR. For example, in XLH and ARHR, expression of MEPE and several bone proteases including cathepsins, ECEL1/DINE, and NEP are markedly increased (37–39, 48, 55) resulting in excess ASARM peptide production and inhibition of mineralization (, , , , ). In these diseases, specific cleavage of MEPE and/or other bone SIBLING proteins (DSPP, OPN, DMP1, etc.) generates an excess of free protease-resistant ASARM peptides (, ). ASARM peptides are acidic, highly charged, with low Pis and are extraordinarily resistant to a wide range of proteases and have physicochemical similarities to bisphosphonates, phosphonoformic acid (PFA), and phosphonoacetic acid (PAA). Also, they share biological properties in vivo and in vitro with bisphosphonates, PFA, and PAA in that they all inhibit mineralization and interfere with renal phosphate handling and vitamin D metabolism (, , –, –, , , , , ). Much work remains to be done to confirm the proposed speculative model presented in the above scheme.